what company makes retatrutide Who Retatrutide? Behind the Weight Loss Drug Retatrutide Triple Agonist (GLP-1/GIP/GCG) |

1 As the first GLP-1RA approved for type 2 diabetes

VLEKT is characterized by a very low total energy intake (650800 kcal per day), carbohydrate restriction to less than 30 g/day, fat intake of around 20 g/day with a preference for sources of unsaturated fats such as extra-virgin olive oil, and protein intake of 0.81.2 g/kg of reference body weight (i.e., calculated based on the patient's height) ( MAD was developed in 2003 as an alternative to the conventional KD, particularly in the context of treating drug-resistant epilepsy ( MCTKD was developed in 1971 by Huttenlocher et al

effect may be limited

The extra weight leads to an increase in the NNMT enzyme, leading to slower fat metabolism, leading to excess weight gain